Technology | October 20, 2011

GE Healthcare Highlights Latest Nuclear Imaging Technology at RSNA 2011

GE Healthcare looks to the future of molecular imaging through improving cost, quality and access by helping clinicians deliver responsible care, both clinically and economically. This includes a focus on positron emission tomography (PET) treatment assessment, reinforced by a portfolio of quantitative imaging tools to help clinicians detect, diagnose and monitor disease earlier, and to evaluate cancer treatment efficacy more quickly.

GE Healthcare has created Q.Suite, a collection of next-generation capabilities designed to further quantitative PET by generating more, consistent standard uptake values readings — and enabling clinicians to assess treatment response more accurately than ever before.

In nuclear medicine, GE will showcase innovative and advanced technology, specifically the Discovery NM/CT 670, designed to improve workflow, dose management, and overall image quality.

The Discovery NM/CT 670 system combines a newly designed SPECT gantry and GE Healthcare’s latest advancements in nuclear medicine detectors with GE Healthcare’s BrightSpeed Elite 16 slice computed tomography (CT), resulting in shorten acquisition times and enabling more convenient patient scheduling in comparison to separate, conventional single photom emission computed tomography (SPECT) and CT exams. With the Discovery NM/CT 670, the imaging time can be reduced from an average of 35 minutes to as little as 16 minutes. After a successful global launch, the system has been selected by 100 sites around the world. The new GE Healthcare Discovery NM630 is engineered to help accommodate more patients than previous generation GE nuclear medicine systems. With its wide bore and table capable of handling patients up to 500 pounds.

Brivo NM615 will make its global debut at RSNA. Brivo NM615, an advanced nuclear medicine gamma camera, is made possible through GE’s innovative Evolution technology. This single head system has the ability to achieve shortened scan times, rivaling a dual head system. Both Discovery systems include SPECT capability that gives doctors the ability to lower injected patient dose by as much as 50 percent of those of standard nuclear medicine scanning protocols, or the potential for patients to spend significantly less time on the table during exams, without compromising image quality.

Also to be showcased:

• Discovery MB750b, a molecular breast imaging system that may assist in assessment and early detection of breast cancer in women who are at high risk for the disease.

• Alcyone technology, adopted by more than 100 leading clinicians worldwide, has become an accepted technology for nuclear cardiology diagnosis. Harnessing four advanced nuclear imaging innovations, Alcyone technology has the ability to reduce scan time and/or injected dose while maintaining image quality. Alcyone technology is available on the Discovery NM 530c.

For more information: www.gehealthcare.com

 

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init